Can you answer the questions about this case ahead of joining Dr Lizaola-Mayo's session by clicking here.

You're seeing a 54-year-old woman in your clinic today. She has a history of class I obesity and type 2 diabetes, currently managed with insulin. She's heard about fatty liver disease and is concerned she might be at risk. Her liver enzymes are normal, but given her risk factors, you decide to calculate a FIB-4 score, which comes back elevated. A subsequent FibroScan reveals stage 3 fibrosis, confirming your suspicions. You now face the challenge of explaining this diagnosis to your patient and discussing the best path forward, particularly considering the potential benefits of various therapeutic options for MASH.

This case highlights the prevalence of MASH and the importance of early detection and intervention. It also underscores the need for healthcare professionals to stay informed about the latest evidence-based treatment options for this condition. By participating in this educational program, you'll gain valuable insights into the management of MASH and develop the skills to provide optimal care for your patients.

This program is funded by an independent grant from Novo Nordisk. This online education program has been designed solely for healthcare professionals in USA. The content is not available for healthcare professionals in any other region.